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The editors of Contemporary Issues in Women’s
Health solicit reporters and correspondents from
throughout the world to make contributions to this
section. Please feel free to e-mail or otherwise con-
tract Dr. Timothy Johnson at trbj@umich.edu or
Prof. S. Arulkumaran at s.arulkumaran@sghms.
ac.uk if you have reports or stories that you would
like to have included. We would be happy to attrib-
ute the items to those reporters and correpondents
who give permission in their transmittal. Other-
wise, we will share those reports that we think are
of the greatest interest to our readership without
attribution.
More (data), more (implications), more
(reactions) from the Women’s Health Initiative
and other fronts regarding hormone therapy
(HT)
As we made final corrections on the following
paragraphs, yet another notification was received:
‘The National Heart, Lung and Blood Institute will
make an announcement regarding the estrogen-
only arm of the Women’s Health Initiative (WHI)
at 9:00 am on March 2, 2004.’ For up-to-date
information, see www.nhlbi.nih.gov/whi.
We previously reported in this column on
the Women’s Health Initiative (WHI) an NIH-
funded project (Int J Gynecol Obstet 2002;79:1–4)
that, in 2002, reported results on the effect of com-
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bined hormone therapy on cardiovascular disease
(www.nhlbi.nih.gov/whiy). Since then, several
new reports have appeared. The Women’s Health
Initiative Memory Study (WHIMS), a subgroup of
the WHI, investigated the incidence of probable
dementia and mild cognitive impairment in 4532
postmenopausal WHI participants 65 and older
who were free of probable dementia at baseline.
The results demonstrated that combined hormone
therapy increased the risk of stroke, dementia, and
global cognitive decline, and did not protect
against mild cognitive impairment. (JAMA
2003;289:2651–2662) Alzheimer’s disease was
the most common classification of dementia in
both study groups, and the hormone therapy did
not significantly prevent mild cognitive impair-
ment. The continued findings of cerebrovascular
risks associated with estrogen plus progestin ther-
apy, coupled with the current findings from
WHIMS, strongly advocate against recommending
hormone replacement therapy ‘for prevention of
any outcome, including Alzheimer’s disease.’
In another WHI study (Hays et al., ‘Effects of
estrogen plus progestin on health-related qualify of
life,’ N Engl J Med 2003:348:1939-1854), which
assessed health-related quality of life, estrogen plus
progesterone, resulted in no significant effects on
‘general health, vitality, mental health, depressive
symptoms, or sexual satisfaction« Among women
age 50 to 54 years of age with moderate to severe
vasomotor symptoms at base line, estrogen and
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progesterone improved vasomotor symptoms and
resulted in a small benefit in terms of sleep distur-
bance but no benefit in terms of other quality-of-
life outcomes.’
The Food and Drug Administration is requesting
that manufacturers update labeling for hormone
therapy products (estrogen and combination estro-
gen and progestin products) for use by postmeno-
pausal women with data from WHIMS.
(www.fda.gov/bbs/topics and www.fda.gov/cder/
infopage/estrogens-progestins/default.htm). The
FDA has previously updated labeling to reflect the
findings of the Women’s Health Initiative with
respect to cardiovascular disease, breast disease
and cancer. The suggested updated labeling and
revised labeling guidance include information
about current approved uses of the drugs. ‘Estrogen
and combined estrogen with progestin products are
effective for treating moderate to severe hot flashes
and night sweats, moderate to severe vaginal dry-
ness, and prevention of osteoporosis associated
with menopause.’ The suggested label states that
if these products are prescribed solely for vaginal
symptoms, health care providers are advised to
consider the use of topical vaginal products. ‘Man-
ufacturers should include WHIMS data in the
existing Black Box that contains WHI data on car-
diovascular risks based on the WHI study.’
In a recent issue of Lancet (Chlebowski RT, Col
N. ‘Commentary: Menopausal hormone therapy
after breast cancer,’ Lancet 2004;363:410-011 and
Holmberg L, Anderson H, ‘HABITS (hormone
replacement therapy after breast cancer)—is it
safe? A randomized comparison: trial stopped’,
Lancet 2004;363:453–55) the early cessation of a
trial of ‘HRT after breast cancer’ in Europe was
announced because of an excess risk of new breast
cancer events.
The rapidity with which this type of data is
reaching patients worldwide is remarkable. (Mac-
Lennan AH, ‘The trials and tribulations of long-
term postmenopausal hormone therapy.’ Obstet
Gynecol Survey 59;2004:65-67) The important
lesson is that well-designed clinical and random-
ized clinical trials such as these have the possibility
to change practice much more rapidly and be trans-
mitted to patients much more rapidly than ever in
the past. Keeping up-to-date is more important
than ever and the internet will be a key resource
for physicians, public agencies, and patients. Hope-
fully, this will ultimately improve health and
patient care.
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New insights into pre-eclampsiaytoxemia
Accumulating reports suggest a new target and
direction to explain the etiology of the disease
called pre-eclampticytoxemia, or EPH gestosis,
which continues to elude our understanding—as
evidenced by the many names for the disease. A
recent publication (N Engl J Med 2004;350:672-
83) provides further evidence of an abnormality
present in those patients destined to develop pre-
eclampsia. Following initial data publication in the
Journal of Clinical Investigation (J Clin Invest
2003:111,649-58) the authors from Beth Israel
Hospital have followed up using samples from the
National Institutes of Health already collected as
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part of a randomized clinical trial on the disease.
They find increased levels of soluble fms-like tyro-
sine kinase 1 (sFlt-1) and reduced levels of pla-
cental growth factor (PlGF) in women in which
pre-elampsia develops.
It appears that study in molecular genetics is
giving us new insight into this ‘great obstetric syn-
drome’ and that a genetic defect in association with
other factors may be etiologic—although we have
been wrong in our suppositions about this disease
before. Stay tuned for updates.
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